PEPG - pepgen.com Debt to Book Capitalization Ratio

Corporate company logo of PepGen Corp (PEPG)

High R&D expenses are keeping the operating leverage of PepGen Inc. (PEPG) in the negative, which is confirmed by the debt-to-equity ratio on this GURU.Markets platform chart, where the 0.13 level represents the current value. The business relies on non-cyclical demand in neuromedicine, yet faces a fierce struggle for drug delivery efficiency into cells.

PepGen Inc (PEPG) - Debts to Book Value from 04/28/2023 to 10/27/2026
Flagship merchandise of PepGen

For PepGen Inc. (PEPG), which implements robotic bioscreening into drug development, this indicator determines capital dependence on borrowed funds. The metric compares total liabilities with the actual value of net assets, revealing the balance between financial leverage and equity. By analyzing the financing structure—debt to book capitalization—an investor assesses the cost of debt service. An increase in this ratio may reflect investments in synthesizer automation. The stability of this coefficient confirms the sustainability of the company's technological development.

Competitors of PepGen Inc.

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio Viking Therapeutics VKTX|Debts to Book Capitalization Ratio supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Biohaven Corp BHVN|Debts to Book Capitalization AMLX|TRVI - Debt to Net Assets|Debts to Book Capitalization PRAX|AVXL (Anavex) - Debts to Book Value|Debt to Book Capitalization Ratio CeriBell Corp (CBLL)|Debt to Book Value Ratio prothena.com (PRTA)|Alector, Inc. (ALEC) - Debt to Book Value|Debt to Net Assets Ratio annexonbio.com (ANNX)|Debts to Book Capitalization OMER|Neurogene Inc - Debts to Net Assets|AC Immune Corp (ACIU) - Debt to Book Capitalization Ratio|VYGR - Debt to Book Value Ratio|NMRA (Neumora Therapeutics) - Debts to Book Capitalization|Debt to Book Value scilexholding.com|TVGN: Debt to Book Value|Debts to Net Assets ACOG|CGTX - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Inhibikase Pharma (IKT)|SAVA: Debts to Book Capitalization|Assertio Holdings - Debts to Book Value|Debt to Book Capitalization Ratio Coya|VTGN - Debts to Book Capitalization Ratio|Debts to Book Capitalization OVID (ovidrx.com)|ABOS (Acumen Pharmaceuticals, Inc) - Debt to Net Assets|Debt to Book Capitalization Ratio CervoMed Inc. (CRVO)|Debt to Book Value Ratio Alterity Therapeutics Ltd|Clene Inc. - Debts to Book Capitalization|Debts to Book Value Jupiter Neurosciences, Inc. JUNS|Debt to Book Value RLMD (Relmada)|Annovis Bio Corporation - Debts to Book Capitalization|Debt to Book Capitalization Ratio Grace Tx (GRCE)|AIFF: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio KLTO|NRSN (NeuroSense Therapeutics Ltd.) - Debts to Book Value|Debt to Book Capitalization Ratio Reviva Pharmaceuticals Holdings RVPH|Debts to Book Capitalization Ratio MetaVia, Inc.|NeurAxis, Inc. - Debts to Book Capitalization|Debts to Book Value HSDT (heliusmedical.com)|Passage Bio (PASG) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Neuphoria Therapeutics, Inc. NEUP|Debts to Book Capitalization NERV|ATHA - Debt to Net Assets|Debts to Book Capitalization ADXN|ALZN (Alzamend Neuro) - Debts to Book Value|Debt to Book Capitalization Ratio Cyclerion Therapeutics Inc. (CYCN)|Debt to Book Value Ratio Protagenic (PTIX)|Pasithea Therapeutics (KTTA) - Debt to Book Value|Debt to Net Assets Ratio cortigent.com (CRGT)|Debts to Book Capitalization ATXI|brainstorm-cell.com - Debts to Net Assets|Cara Therapeutics (CARA) - Debt to Book Capitalization Ratio|CHRO - Debt to Book Value Ratio|ELYM (eliemtx.com) - Debts to Book Capitalization|Debt to Book Value Intra-Cellular Therapies, Inc.|LBPH: Debt to Book Value|Debts to Net Assets MRNS|NKGN - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio NeuroBo Pharmaceuticals Inc (NRBO)|SAGE: Debts to Book Capitalization|Synaptogenix, Inc - Debts to Book Value|Debt to Book Capitalization Ratio Trevena, Inc.|VIGL - Debts to Book Capitalization Ratio|Debts to Book Capitalization WENA (Anew Medical)|CERE (Cerevel Therapeutics Inc) - Debt to Net Assets